Global analysis of differentially expressed genes in androgen-independent prostate cancer

被引：30
|
作者：
Wei, Q.
Li, M.
Fu, X.
Tang, R.
Na, Y.
Jiang, M.
Li, Y. [1 ]
机构：
[1] Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China
[2] Peking Univ, First Hosp, Dept Urol, Beijing 100871, Peoples R China
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2007年 / 10卷 / 02期
基金：
中国国家自然科学基金;
关键词：
androgen independent; expression profile; hormone; angiogenesis; microarray;
D O I：
10.1038/sj.pcan.4500933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Progression to androgen independent ( AI) is the main cause of death in prostate cancer, and the mechanism is still unclear. By reviewing the expression profiles of 26 prostate cancer samples in a holistic view, we found a group of genes differentially expressed in AI compared with androgen-dependent groups ( P- value < 0.01, t- test). Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5, tumor necrosis factor receptor superfamily, member 10a, ribosomal protein S19 and Janus kinase 2 upregulated in AI prostate cancer, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.
引用
收藏
页码：167 / 174
页数：8
相关论文
共 50 条
  • [31] Protein kinase C-α:: A novel target for the therapy of androgen-independent prostate cancer? (Review-hypothesis)
    O'Brian, CA
    ONCOLOGY REPORTS, 1998, 5 (02) : 305 - 309
  • [32] Matrine inhibits proliferation and induces apoptosis of the androgen-independent prostate cancer cell line PC-3
    Zhang, Peng
    Wang, Ziming
    Chong, Tie
    Ji, Zongzheng
    MOLECULAR MEDICINE REPORTS, 2012, 5 (03) : 783 - 787
  • [33] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
    Drake, MJ
    Robson, W
    Mehta, P
    Schofield, I
    Neal, DE
    Leung, HY
    BRITISH JOURNAL OF CANCER, 2003, 88 (06) : 822 - 827
  • [34] Angiopoietin-like protein 2 induces androgen-independent and malignant behavior in human prostate cancer cells
    Sato, Ryuta
    Yamasaki, Mutsushi
    Hirai, Kenichi
    Matsubara, Takanori
    Nomura, Takeo
    Sato, Fuminori
    Mimata, Hiromitsu
    ONCOLOGY REPORTS, 2015, 33 (01) : 58 - 66
  • [35] Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells
    Handayani, R
    Rice, L
    Cui, YH
    Medrano, TA
    Samedi, VG
    Baker, HV
    Szabo, NJ
    Shiverick, KT
    JOURNAL OF NUTRITION, 2006, 136 (01): : 75 - 82
  • [36] Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes
    Rodney, A
    Dieringer, P
    Mathew, P
    Jonasch, E
    Tannir, N
    Pagliaro, LC
    CANCER, 2006, 106 (10) : 2143 - 2147
  • [37] Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study
    Fossa, Sophie D.
    Jacobsen, Anne-Birgitte
    Ginman, Claes
    Jacobsen, Inga N.
    Overn, Sissel
    Iversen, Jon R.
    Urnes, Thomas
    Dahl, Alv A.
    Veenstra, Marijke
    Sandstad, Berit
    EUROPEAN UROLOGY, 2007, 52 (06) : 1691 - 1699
  • [38] Phase II trial of GM-CSF plus thalidomide in patients with androgen-independent metastatic prostate cancer
    Dreicer, R
    Klein, EA
    Elson, P
    Peereboom, D
    Byzova, T
    Plow, EF
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (02) : 82 - 86
  • [39] Prognostic factors for survival among Caucasian, African-Amercan and Hispanic men with androgen-independent prostate cancer
    Wyatt, RB
    Sánchez-Ortiz, RF
    Wood, CG
    Ramirez, E
    Logothetis, C
    Pettaway, CA
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2004, 96 (12) : 1587 - 1593
  • [40] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
    M J Drake
    W Robson
    P Mehta
    I Schofield
    D E Neal
    H Y Leung
    British Journal of Cancer, 2003, 88 : 822 - 827
12345